Proteomics of breast cancer: Outcomes and prospects

Technology in Cancer Research and Treatment

Volumn 1, Issue 4, 2002, Pages 287-295

  El Yazidi Belkoura, Ikram ^a   Adriaenssens, Eric ^a   Vercoutter Edouart, Anne Sophie ^b   Lemoine, Jérôme ^b   Nurcombe, Victor ^c   Hondermarck, Hubert ^a  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DES SCIENCES ET TECHNOLOGIES DE LILLE   (France)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Breast cancer; Marker; Proteomics; Signaling pathways; Therapeutic targets

Indexed keywords

CHAPERONE; FIBROBLAST GROWTH FACTOR 2; TUMOR MARKER; UNTRANSLATED RNA;

ARTICLE; BIOINFORMATICS; BREAST CANCER; CANCER STAGING; CARCINOGENESIS; GENE SEQUENCE; HUMAN GENOME; MASS SPECTROMETRY; ONCOGENE; PROTEIN ANALYSIS; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR DIFFERENTIATION; UNTRANSLATED REGION;

EID: 0037884876     PISSN: 15330346     EISSN: None     Source Type: Journal    
DOI: 10.1177/153303460200100410     Document Type: Article

References (61)

1. Wright, G. L. Jr. Two-dimensional acrylamide gel electrophoresis of cancer-patient serum proteins. Ann. Clin. Lab. Sci. 4, 281-293 (1974).
2. Westley, B., and Rochefort, H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell 20, 353-362 (1980).
3. Stastny, J., Prasad, R., Fosslien, E. Tissue proteins in breast cancer, as studied by use of two-dimensional electrophoresis. Clin. Chem. 30, 1914-1918 (1984).
4. Wirth, P. J., Egilsson, V., Gudnason, V., Ingvarsson, S., and Thorgeirsson, S. S. Specific polypeptide differences in normal versus malignant human breast tissues by two-dimensional electrophoresis. Breast Cancer Res. Treat. 10, 177-189 (1987).
5. Worland, P. J., Bronzert, D., Dickson, R. B., Lippman, M. E., Hampton, L., Thorgeirsson, S. S., and Wirth, P. J. Secreted and cellular polypeptide patterns of MCF-7 human breast cancer cells following either estrogen stimulation or v-H-ras transfection. Cancer Res. 49, 51-57 (1989).
6. Maloney, T. M., Paine, P. L., and Russo, J. Polypeptide composition of normal and neoplastic human breast tissues and cells analyzed by two-dimensional gel electrophoresis. Breast Cancer Res. Treat. 14, 337-348 (1989).
7. Trask, D. K., Band, V., Zajchowski, D. A., Yaswen, P., Suh, T., and Sager, R. Keratins as markers that distinguish normal and tumor-derived mammary epithelial cells. Proc. Natl. Acad. Sci. USA 87, 2319-2323 (1990).
8. Giometti, C. S., Tollaksen, S. L., Chubb, C., Williams, C., Huberman, E. Analysis of proteins from human breast epithelial cells using two-dimensional gel electrophoresis. Electrophoresis 16, 1215-1224 (1995).
9. Bhattacharya, B., Prasad, G. L., Valverius, E. M., Salomon, D. S., and Cooper, H. L. Tropomyosins of human mammary epithelial cells: consistent defects of expression in mammary carcinoma cell lines. Cancer Res. 50, 2105-2112 (1990).
10. Franzen, B., Linder, S., Okuzawa, K., Kato, H., and Auer, G. Non enzymatic extraction of cells from clinical tumor material for analysis of gene expression by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 14, 1045-1053 (1993).
11. Franzen, B., Linder, S., Alaiya, A. A., Eriksson, E., Uruy, K., Hirano, T., Okuzawa, K., and Auer, G. Analysis of polypeptide expression in benign and malignant human breast lesions: down-regulation of cytokeratins. Br. J. Cancer 74, 1632-1638 (1996).
12. Franzen, B., Linder, S., Alaiya, A. A., Eriksson, E., Fujioka, K., Bergman, A. C., Jornvall, H., and Auer, G. Analysis of polypeptide expression in benign and malignant human breast lesions. Electrophoresis 18, 582-587 (1997).
13. Williams, K., Chubb, C., Huberman, E., and Giomettì, C. S. Analysis of differential protein expression in normal and neoplastic human breast epithelial cell lines. Electrophoresis 19, 333-343 (1998).
14. Page, M. J., Amess, B., Townsend, R. R., Parekh, R., Herath, A., Brusten, L., Zvelebil, M. J., Stein, R. C., Waterfield, M. D., Davies, S. C., and O'Hare, M. J. Proc. Natl. Acad. Sci. USA 96, 12589-12594 (1999).
15. Bergman, A. C., Benjamin, T., Alaiya, A., Waltham, M., Sakaguchi, K., Franzen, B., Linder, S., Bergman, T., Auer, G., Appella, E., Wirth, P. J., and Jornvall, H. Identification of gel-separated tumor marker proteins by mass spectrometry. Electrophoresis 21, 679-686 (2000).
16. Vercoutter-Edouart, A. S., Lemoine, J., Le Bourhis, X., Louis, H., Boilly, B., Nurcombe, V., Revillion, F., Peyrat, J. P., and Hondermarck, H. Proteomic analysis reveals that 14-3-3sigma is down-regulated in human breast cancer cells. Cancer Res. 61, 76-80 (2001).
17. Fu, H., Subramanian, R. R., and Masters, S. C. 14-3-3 proteins: structure, function, and regulation. Annu. Rev. Pharmacol. Toxicol. 40, 617-647 (2000).
18. Aprelikova, O., Pace, A. J., Fang, B., Koller, B. H., and Liu, E. T. BRCA1 is a selective co-activator of 14-3-3 sigma gene transcription in mouse embryonic stem cells. J. Biol. Chem. 276, 25647-50 (2001).
19. Ferguson, A. T., Evron, E., Umbricht, C. B., Pandita, T. K., Chan, T. A., Hermeking, H., Marks, J. R., Lambers, A. R., Futreal, P. A., Stampfer, M. R., and Sukumar, S. High frequency of hypermethylation at the 14-3-3 sigma locus leads to gene silencing in breast cancer. Proc. Natl. Acad. Sci. USA 97, 6049-6054 (2000).
20. Craven, R. A., and Banks, R. E. Laser capture microdissection and proteomics: possibilities and limitation. Proteomics 1, 1200-4 (2001).
21. Haber, D. Roads leading to breast cancer. N. Engl. J. Med. 343, 1566-1568 (2000).
22. Osborne, C. K. Tamoxifen in the treatment of breast cancer. N. Engl. J. Med. 339, 1609-1618 (1998).
23. Ethier, S. P. Growth factor synthesis and human breast cancer progression. J. Natl. Cancer Inst. 87, 964-973 (1995).
24. Le Bourhis, X., Toillon, R. A., Boilly, B., and Hondermarck, H. Autocrine and paracrine growth inhibition of breast cancer cells. Breast Cancer Res. Treat. 1722, 1-8 (2000).
25. Nurcombe, V., Smart, C. E., Chipperfield, H., Cool, S. M., Boilly, B., and Hondermarck, H. The proliferative and migratory activities of breast cancer cells can be differentially regulated by heparan sulfates. J. Biol. Chem. 275, 30009-30018 (2000).
26. Descamps, S., Lebourhis, X., Delehedde, M., Boilly, B., and Hondermarck, H. Nerve growth factor is mitogenic for cancerous but not normal human breast epithelial cells. J. Biol. Chem. 273, 16659-16662 (1998).
27. Descamps, S., Toillon, R. A., Adriaenssens, E., Pawlowski, V., Cool, S. M., Nurcombe, V., Le Bourhis, X., Boilly, B., Peyrat, J. P., and Hondermarck, H. Nerve growth factor stimulates proliferation and survival of human breast cells through two distinct signaling pathways. J. Biol. Chem. 276, 17864-70 (2001).
28. Hondermarck, H., Vercoutter-Edouart, A. S., Revillion, F., Lemoine, J., El Yazidi-Belkoura, I., Nurcombe, V., and Peyrat, J. P. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1, 1216-32 (2001).
29. Godovac-Zimmermann, J., Soskic, V., Poznanovic, S., and Brianza, F. Functional proteomics of signal transduction by membrane receptors. Electrophoresis 20, 952-61 (1999).
30. Steen, H., Kuster, B., Fernandez, M., Pandey, A., and Mann, M. Tyrosine phosphorylation mapping of the epidermal growth factor receptor signaling pathway. J. Biol. Chem. 277, 1031-9 (2002).
31. Vercoutter, A. S., Lemoine, J., Smart, C. E., Nurcombe, V., Boilly, B., Peyrat, J. P., and Hondermarck, H. The mitogenic signaling pathway for fibroblast growth factor-2 involves the tyrosine phosphorylation of cyclin D2 in MCF-7 human breast cancer cells. FEBS Lett., 478, 209-215 (2000).
32. Hondermarck, H., McLaughlin, C. S., Patterson, S. D., and Bradshaw, R. A. Early changes in protein synthesis induced by basic fibroblast growth factor, nerve growth factor, and epidermal growth factor in PC12 pheochromocytoma cells. Proc. Natl. Acad. Sci. USA 91, 9377-9381 (1994).
33. Soskic, V., Gorlach, M., Poznanovic, S., Boehmer, F. D., and Godovac-Zimmermann, J. Functional proteomics analysis of signal transduction pathways of the platelet-derived growth factor beta receptor. Biochemistry 38, 1757-1764 (1999).
34. Pandey, A., Podtelejnikov, A. V., Blagoev, B., Bustelo, X. R., Mann, M., and Lodish, H. F. Analysis of receptor signaling pathways by mass spectrometry: identification of vav-2 as a substrate of the epidermal and platelet-derived growth factor receptors. Proc. Natl. Acad. Sci. USA 97, 179-184 (2000).
35. McKeehan, W. L., Wang, F., and Kan, M. The heparan sulfatefibroblast growth factor family: diversity of structure and function. Prog. Nucleic Acid Res. Mol. Biol. 59, 135-176 (1998).
36. Adnane, J., Gaudray, P., Dionne, C. A., Crumley, G., Jaye, M., Schlessinger, J., Jeanteur, P., Birnbaum, D., and Theillet, C. BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene 6, 659-662 (1991).
37. Blanckaert, V. D., Hebbar, M., Louchez, M. M., Vilain, M. O., Schelling, M. E., Peyrat, J. P. Basic fibroblast growth factor receptors and their prognostic value in human breast cancer. Clin. Cancer Res. 4, 2939-2947 (1998).
38. Rahmoune, H., Chen, H. L., Gallagher, J. T., Rudland, P. S., and Femig, D. G. Interaction of heparan sulfate from mammary cells with acidic fibroblast growth factor (FGF) and basic FGF. Regulation of the activity of basic FGF by high and low affinity binding sites in heparan sulfate. J. Biol. Chem. 273, 7303-7310 (1998).
39. Liu, J. F., Chevet, E., Kebache, S., Lemaitre, G., Barritault, D., Larose, L., and Crepin, M. Functional Rac-1 and Nck signaling networks are required for FGF-2-induced DNA synthesis in MCF-7 cells. Oncogene 18, 6425-6433 (1999).
40. Vercoutter-Edouart A. S., Czeszak, X., Crepin, M., Lemoine, J., Boilly, B., Le Bourhis, X., Peyrat, J. P., and Hondermarck, H. Proteomic detection of changes in protein synthesis induced by fibroblast growth factor-2 in MCF-7 human breast cancer cells. Exp. Cell Res. 262, 59-68 (2001).
41. Jolly, C., and Morimoto, R. I. Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J. Natl. Cancer Inst. 92, 1564-1572 (2000).
42. Brannan, C. I., Dees, E. C., Ingram, R. S., and Tilghman, S. M. The product of the H19 gene may function as an RNA. Mol. Cell Biol. 10, 28-36 (1990).
43. Hao, Y., Crenshaw, T., Moulton, T., Newcomb, E., and Tycko, B. Tumour-suppressor activity of H19 RNA. Nature 365, 764-7 (1993).
44. Lottin, S., Vercoutter-Edouart, A. S., Adriaenssens, E., Czezak, X., Lemoine, J., Roudbaraki, M., Coll, J., Hondermarck, H., Dugimont, T., and Curgy, J. J. Thioredoxin post-transcriptional regulation by H19 provides a new function to non-coding mRNA. Oncogene 21, 1625-31 (2002).
45. Nakamura, H., Nakamura, K., and Yodoi, J. Redox regulation of cellular activation. Annu. Rev. Immunol. 15, 351-69 (1997).
46. Hirota, K., Murata, M., Itoh, T., Yodoi, J., and Fukuda, K. Redoxsensitive transactivation of epidermal growth factor receptor by tumor necrosis factor confers the NF-kappa B activation. J Biol. Chem. 276, 25953-8 (2001).
47. Adriaenssens, E., Lottin, S., Berteaux, N., Hornez, L., Fauquette, W., Fafeur, V., Peyrat, J. P., LeBourhis, X., Hondermarck, H., Coll, J., Dugimont, T., and Curgy, J. J. Cross-talk between mesenchyme and epithelium increases H19 gene expression during scatttering and morphogenesis of epithelial cells. Exp. Cell Res. 275, 215-29 (2002).
48. Colomer, R., Shamon, L. A., Tsai, M. S., and Lupu, R. Herceptin: from the bench to the clinic. Cancer Invest. 19, 49-56 (2001).
49. Jain, K. K. Proteomics: new technologies and their applications. Drug Discov Today 6, 457-459 (2001).
50. Li, S., and Shipley, G. D. Expression of multiple species of basic fibroblast growth factor mRNA and protein in normal and tumor-derived mammary epithelial cells in culture. Cell Growth Diff. 2, 195-202 (1991).
51. Laronga, C., Yang, H. Y., Neal, C., and Lee, M. H. Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progression. J. Biol. Chem. 275, 23106-23112 (2000).
52. Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., and Aebersold, R. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat. Biotechnol. 17, 994-999 (1999).
53. Gygi, S. P, and Aebersold, R. Mass spectrometry and proteomics. Curr. Opin. Chem. Biol. 4, 489-494 (2000).
54. Patterson, S. D. Mass spectrometry and proteomics. Physiol. Genomics 2, 59-65 (2000).
55. Kumar, A. and Snyder, M. Protein complexes take the bait. Nature 415, 123-4 (2002).
56. Weinberger, S. R, Morris, T. S, and Pawlak, M. Recent trends in protein biochip technology. Pharmacogenomics 1, 395-416 (2000).
57. Jain, K. K. Post-genomic applications of lab-on-a-chip and microarrays. Trends Biotechnol. 20, 184-5 (2002).
58. Nelson, R. W., Nedelkov, D., and Tubbs, K. A. Biosensor chip mass spectrometry: a chip-based proteomics approach. Electrophoresis 21, 1155-63 (2000).
59. Fung, E. T., Thulasiraman, V., Weinberger, S. R., and Dalmasso, E. A. Protein biochips for differential profiling. Curr. Opin. Biotechnol. 12, 65-69 (2001).
60. Celis, J. E., Kruhoffer, M., Gromova, I., Frederiksen, C., Ostergaard, M., Thykjaer, T., Gromov, P., Yu, J., Palsdottir, H., Magnusson, N., Orntoft, T. F. Gene expression profiling: monitoring transcription and translation products using DNA microarrays and proteomics. FEBS Lett 480, 2-16 (2000).
61. Hanash, S. M. Global profiling of gene expression in cancer using genomics and proteomics. Curr. Opin. Mol. Ther. 3, 538-45 (2001).